Roche Pegasys Combination Yields 12% Greater Viral Response Vs. Rebetron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche’s pegylated interferon Pegasys plus ribavirin demonstrated a significant increase in efficacy over Schering Plough’s interferon-ribavirin combination product Rebetron in a study that will be submitted to the New England Journal of Medicine, Roche said.